首页> 外文OA文献 >A Novel Imaging System Permits Real-time in Vivo Tumor Bed Assessment After Resection of Naturally Occurring Sarcomas in Dogs
【2h】

A Novel Imaging System Permits Real-time in Vivo Tumor Bed Assessment After Resection of Naturally Occurring Sarcomas in Dogs

机译:一种新型成像系统允许在犬切除自然发生的肉瘤后进行实时体内肿瘤床评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundTreatment of soft tissue sarcoma (STS) includes complete tumor excision. However, in some patients, residual sarcoma cells remain in the tumor bed. We previously described a novel hand-held imaging device prototype that uses molecular imaging to detect microscopic residual cancer in mice during surgery.Questions/purposesTo test this device in a clinical trial of dogs with naturally occurring sarcomas, we asked: (1) Are any adverse clinical or laboratory effects observed after intravenous administration of the fluorescent probes? (2) Do canine sarcomas exhibit fluorescence after administration of the cathepsin-activated probe? (3) Is the tumor-to-background ratio sufficient to distinguish tumor from tumor bed? And (4) can residual fluorescence be detected in the tumor bed during surgery and does this correlate with a positive margin?MethodsWe studied nine dogs undergoing treatment for 10 STS or mast cell tumors. Dogs received an intravenous injection of VM249, a fluorescent probe that becomes optically active in the presence of cathepsin proteases. After injection, tumors were removed by wide resection. The tumor bed was imaged using the novel imaging device to search for residual fluorescence. We determined correlations between tissue fluorescence and histopathology, cathepsin protease expression, and development of recurrent disease. Minimum followup was 9 months (mean, 12 months; range, 9–15 months).ResultsFluorescence was apparent from all 10 tumors and ranged from 3 × 107 to 1 × 109 counts/millisecond/cm2. During intraoperative imaging, normal skeletal muscle showed no residual fluorescence. Histopathologic assessment of surgical margins correlated with intraoperative imaging in nine of 10 cases; in the other case, there was no residual fluorescence, but tumor was found at the margin on histologic examination. No animals had recurrent disease at 9 to 15 months.ConclusionsThese initial findings suggest this imaging system might be useful to intraoperatively detect residual tumor after wide resections.Clinical RelevanceThe ability to assess the tumor bed intraoperatively for residual disease has the potential to improve local control.
机译:背景技术治疗软组织肉瘤(STS)包括完全切除肿瘤。但是,在某些患者中,残留的肉瘤细胞保留在肿瘤床中。先前我们描述了一种新颖的手持式成像设备原型,该设备使用分子成像技术检测手术过程中小鼠的微小残留癌症。问题/目的为了在具有天然肉瘤的狗的临床试验中测试该设备,我们问:(1)是否静脉内注射荧光探针后是否观察到不良的临床或实验室影响? (2)使用组织蛋白酶激活的探针后,犬肉瘤是否显示荧光? (3)肿瘤与背景的比率是否足以区分肿瘤与肿瘤床? (4)能否在手术过程中在肿瘤床上检测到残留的荧光,这与阳性余量相关吗?方法我们研究了九只接受10种STS或肥大细胞瘤治疗的狗。狗接受了静脉注射VM249,这是一种在组织蛋白酶存在下具有光学活性的荧光探针。注射后,通过广泛切除术去除肿瘤。使用新型成像设备对肿瘤床成像,以寻找残留的荧光。我们确定了组织荧光与组织病理学,组织蛋白酶蛋白酶表达和复发性疾病发展之间的相关性。最小随访时间为9个月(平均12个月;范围9-15个月)。结果所有10个肿瘤均可见荧光,范围从3×107到1×109计数/毫秒/ cm2。在术中成像期间,正常骨骼肌未显示残留荧光。 10例中有9例的手术切缘与术中影像学相关的组织病理学评估;在另一种情况下,没有残留的荧光,但是在组织学检查的边缘发现了肿瘤。在9到15个月内没有动物再发疾病。结论这些最初的发现表明,该成像系统可能对广泛切除后的术中残留肿瘤的诊断有用。临床意义术中评估肿瘤床残留病的能力有可能改善局部控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号